Omrix Biopharmaceuticals Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 212

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $458M

  • Investors
  • 1

Omrix Biopharmaceuticals General Information

Description

Developer and manufacturer of products derived from human plasma. The company develops hemostatic products designed to control bleeding during surgery and immunotherapy

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • One Rockefeller Center
  • Suite 2322
  • New York, NY 10020
  • United States
+1 (212)
Primary Industry
Biotechnology
Acquirer
Johnson & Johnson
Corporate Office
  • One Rockefeller Center
  • Suite 2322
  • New York, NY 10020
  • United States
+1 (212)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Omrix Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 30-Dec-2008 $458M Completed Generating Revenue
8. IPO 21-Apr-2006 Completed Generating Revenue
7. Mezzanine 01-Apr-2005 Completed Generating Revenue
6. Debt - General 01-Mar-2005 Completed Generating Revenue
5. Secondary Transaction - Private 01-Feb-2005 Completed Generating Revenue
4. Later Stage VC (Series B) 05-Aug-2004 Completed Product Development
3. Later Stage VC (Series A) 22-Mar-2001 Completed Product Development
2. Early Stage VC 04-Sep-1999 $20M $35.2M Completed Product Development
1. Early Stage VC 01-Jan-1998 $15.2M $15.2M Completed Product Development
To view Omrix Biopharmaceuticals’s complete valuation and funding history, request access »

Omrix Biopharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Omrix Biopharmaceuticals’s complete cap table history, request access »

Omrix Biopharmaceuticals Patents

Omrix Biopharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2282847-A1 Process and apparatus for coating a porous substrate with a coating liquid Active 22-May-2008
EP-2282847-B1 Process for coating a porous substrate with a coating liquid Active 22-May-2008
ES-2557175-T3 Process for coating a porous substrate with a coating liquid Active 22-May-2008
EP-2124063-A1 Protein assay Active 22-May-2008
EP-2124063-B1 Protein assay Inactive 22-May-2008 C12Q1/56
To view Omrix Biopharmaceuticals’s complete patent history, request access »

Omrix Biopharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Omrix Biopharmaceuticals Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
BRM Group Venture Capital Minority
Capricorn Partners Venture Capital Minority
Carlyle AlpInvest PE/Buyout Minority
Catalyst Investments PE/Buyout Minority
Catalyst Venture Partners Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Omrix Biopharmaceuticals FAQs

  • When was Omrix Biopharmaceuticals founded?

    Omrix Biopharmaceuticals was founded in 1995.

  • Where is Omrix Biopharmaceuticals headquartered?

    Omrix Biopharmaceuticals is headquartered in New York, NY.

  • What is the size of Omrix Biopharmaceuticals?

    Omrix Biopharmaceuticals has 212 total employees.

  • What industry is Omrix Biopharmaceuticals in?

    Omrix Biopharmaceuticals’s primary industry is Biotechnology.

  • Is Omrix Biopharmaceuticals a private or public company?

    Omrix Biopharmaceuticals is a Private company.

  • What is the current valuation of Omrix Biopharmaceuticals?

    The current valuation of Omrix Biopharmaceuticals is .

  • What is Omrix Biopharmaceuticals’s current revenue?

    The current revenue for Omrix Biopharmaceuticals is .

  • How much funding has Omrix Biopharmaceuticals raised over time?

    Omrix Biopharmaceuticals has raised $87.5M.

  • Who are Omrix Biopharmaceuticals’s investors?

    BRM Group, Capricorn Partners, Carlyle AlpInvest, Catalyst Investments, and Catalyst Venture Partners are 5 of 8 investors who have invested in Omrix Biopharmaceuticals.

  • When was Omrix Biopharmaceuticals acquired?

    Omrix Biopharmaceuticals was acquired on 30-Dec-2008.

  • Who acquired Omrix Biopharmaceuticals?

    Omrix Biopharmaceuticals was acquired by Johnson & Johnson.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process